Department of Otolaryngology, Head and Neck Surgery, University of Ottawa, 501 Smyth Rd, Module S - Room M2566, Box 216, Ottawa, ON, K1H 8L6, Canada.
Institute for Clinical and Evaluative Sciences, Queen's University, Abramsky Hall, Room 208, 21 Arch Street, Kingston, ON, K7L 3N6, Canada.
J Otolaryngol Head Neck Surg. 2018 Dec 4;47(1):74. doi: 10.1186/s40463-018-0322-7.
We sought to expand upon preliminary data suggesting that metformin confers a survival benefit to patients with head and neck squamous cell carcinoma (HNSCC).
A large-scale retrospective cohort study of all patients in Ontario diagnosed with squamous cancer of the larynx, hypopharynx, and nasopharynx between Dec 1st 2007 to Dec 1st 2012 was undertaken. The Institute for Clinical and Evaluative Sciences was accessed to obtain patient demographic, treatment and outcome information. We included patients on metformin at the time of diagnosis. Kaplan Meier methods and Cox Regression models were used.
Patients taking metformin at the time of diagnosis had a higher comorbid status but were otherwise similar to patients without metformin usage. Using multivariate analysis, neither overall survival nor disease specific survival was improved in patients on metformin (OS: HR 1.123, p = .338; DSS: HR 1.048, p = .792).
No survival advantage was observed in patients with HNSCC taking metformin at the time of diagnosis.
我们试图扩展初步数据，表明二甲双胍为头颈部鳞状细胞癌（HNSCC）患者带来生存获益。
对 2007 年 12 月 1 日至 2012 年 12 月 1 日期间安大略省所有被诊断为喉、下咽和鼻咽癌的鳞状癌患者进行了一项大型回顾性队列研究。我们访问了临床和评估科学研究所，以获取患者的人口统计学、治疗和结局信息。我们纳入了诊断时正在服用二甲双胍的患者。采用 Kaplan-Meier 方法和 Cox 回归模型。
诊断时正在服用二甲双胍的患者合并症较多，但与未使用二甲双胍的患者无其他差异。多变量分析显示，服用二甲双胍的患者总生存率和疾病特异性生存率均无改善（OS：HR 1.123，p=0.338；DSS：HR 1.048，p=0.792）。
诊断时服用二甲双胍的 HNSCC 患者未观察到生存优势。
